Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0011306,
umls-concept:C0017262,
umls-concept:C0017387,
umls-concept:C0079411,
umls-concept:C0085358,
umls-concept:C0385723,
umls-concept:C0871261,
umls-concept:C1171362,
umls-concept:C1332714,
umls-concept:C1332717,
umls-concept:C1334510,
umls-concept:C1413244,
umls-concept:C1515670,
umls-concept:C1704632,
umls-concept:C1706438,
umls-concept:C1706817,
umls-concept:C2698600,
umls-concept:C2911692
|
pubmed:issue |
23
|
pubmed:dateCreated |
1998-12-31
|
pubmed:abstractText |
Both CD8+ and CD4+ T cells have demonstrated roles in antitumor immune response in many animal tumor systems. In many human tumor systems, although abundant literature exists on the evidence of tumor antigen-specific CD8+ CTL response, only limited information is available on tumor antigen-specific CD4+ T-cell response. Using the MART-1/Melan-A (MART-1) antigen system as a prototype human tumor-associated antigen (TAA)- and dendritic cell (DC)-based MART-1 antigen presentation system (i.e., DCs transduced with an adenoviral vector-based construct carrying the MART-1 gene), we explored, in vitro, the feasibility of generating both CD8+ and CD4+ T-cell responses in the same individual. Here, we show that autologous DCs from both HLA-A2-positive melanoma patients and normal healthy individuals that are transduced with an adenoviral vector containing the MART-1 antigen are capable of inducing both MART-1-specific CD8+ and CD4+ T cells in in vitro coculture. After several rounds of stimulation, both the CD4+ and CD8+ T cells synthesized IFN-gamma when they were specifically stimulated. The CD8+ T cells generated in such cocultures also recognized the MART-1(27-35) peptide, AAGIGILTV, in 4-h cytotoxicity assays. These observations, therefore, suggest that Th1-type responses can be generated, in vitro, by stimulation with DCs that are genetically modified to express a TAA. Although the outcome of this type of genetically engineered DC-based stimulation may vary from system to system, this type of in vitro antigen presentation may be very useful in more comprehensive analyses of CD4+ T-cell response to defined TAAs, and such genetically engineered autologous DCs might be better candidates to serve as surrogate cancer vaccines.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/MART-1 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/MLANA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5305-9
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:9850054-Antigens, Neoplasm,
pubmed-meshheading:9850054-CD4-Positive T-Lymphocytes,
pubmed-meshheading:9850054-CD8-Positive T-Lymphocytes,
pubmed-meshheading:9850054-Cell Communication,
pubmed-meshheading:9850054-Dendritic Cells,
pubmed-meshheading:9850054-Epitopes,
pubmed-meshheading:9850054-Epitopes, T-Lymphocyte,
pubmed-meshheading:9850054-Humans,
pubmed-meshheading:9850054-Lymphocyte Activation,
pubmed-meshheading:9850054-MART-1 Antigen,
pubmed-meshheading:9850054-Melanoma,
pubmed-meshheading:9850054-Neoplasm Proteins,
pubmed-meshheading:9850054-Transduction, Genetic
|
pubmed:year |
1998
|
pubmed:articleTitle |
Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
|
pubmed:affiliation |
Department of Medicine, University of Connecticut Health Center, Farmington 06030, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|